Roar BidCo's outstanding public offer for Recipharm AB - EQT

Recipharm AB Skatteverket

The transaction will be routed through Roar BidCo AB, a limited liability company established on Nov. 10, 2020, wholly-owned by EQT. Why Does It Matter: The purchased consideration is fixed at 220 SEK per share in cash, a 23% premium on 2020-12-14 Stockholm-based EQT has already secured ownership of about 25.7% of the shares and 74.3% of the votes in Recipharm through its chairman, Lars Backsell, and Thomas Eldered, its chief executive. The deal is worth 17.9 billion kronor, or about $2.1 billion. Recipharm specializes in the contract development and manufacture of pharmaceuticals. Köp aktier i EQT - enkelt och billigt hos Avanza Bank.

De innehavda aktierna motsvarar 95,1 procent av aktiekapitalet, framgår det av ett pressmeddelande. EQT höjer budet på Recipharm. Publicerad 2021-01-28 08:29. Foto: Shutterstock. Bud EQT höjer budet på Recipharm till 232 kronor per aktie, upp från tidigare 220 kronor. Men enligt EQT kommer budet inte att höjas ytterligare.

EQT makes $2.8 billion Recipharm employs more than 9,000 employees in Europe, the US and India. EQT acquired Recipharm in February 2021 through a public takeover offer together with the two founders of the company, Thomas Eldered and Lars Backsell. EQT lägger bud på Recipharm.

EQT Infrastructure V launches offer to acquire all outstanding

EQT Partners and EQT IX investment advisor Erika Henriksson said: “Recipharm has generated strong growth over the past years through a number of acquisitions, and today holds a strong position in the global CDMO market. EQT wants to support Recipharm’s continued development, which will require significant and long-term investments.” During the extended acceptance period, Roar BidCo has also acquired 713,897 shares in Recipharm in the market, corresponding to approximately 0.7 per cent ofthe share capital and approximately 0.2 per cent of the voting rights in Recipharm[6]. No acquisitions were made at a price that exceeds the consideration in the Revised Offer. On 11 February 2021, the European Commission announced that it has decided under Article 6(1)(b) of the EU Merger Regulation to approve the acquisition of joint control of Recipharm by EQT… EQT's bid also follows news from Recipharm that a molecule it's developing, Erdosteine, appeared to help Covid patients recover after they were discharged from hospital.

EQT Company News CompanyNewsHQ

Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage.

2020-12-14 · (Dec 14): Private equity firm EQT AB agreed to buy Swedish pharmaceuticals company Recipharm AB for $2.1 billion, marking the latest in a wave of drug industry acquisitions.EQT said Monday it’s offering shareholders 220 kronor in cash per share, 23% more than Friday’s closing price. Recipharm is a 25-year-old company that specializes in outsourcing contract manufacturing services to help We proudly introduce a new addition to the Recipharm family. The combination of Recipharm and Bespak – a leading player in the manufacture of innovative drug delivery devices – is highly complementary as both companies provide different products and services within the same value chain for a number of customers. Read more here. Stockholm headquartered private equity group EQT AB will buy Swedish pharma company Recipharm AB for $2.1 billion, according to company's press release.The transaction will be routed through Roar Riskkapitalbolaget EQT lägger, genom bolaget Roar Bidco, ett bud på kontraktstillverkaren Recipharm. Aktieägare erbjuds 220 kronor per aktie i Recipharm och innehavare av konvertibler erbjuds drygt 1,4 miljoner kronor per konvertibel med ett nominellt belopp på 1,0 miljoner kronor, enligt ett pressmeddelande.
Introvert personlighet yrke

Bolagets båda grundare, ordföranden Lars Backsell och vd:n till aktieägarna och Konvertibelinnehavarna i Recipharm AB (publ) EQT tar nästa steg i Asien-Stillahavsområdet – öppnar kontor i Japan to the voluntary offer (the "Offer") to acquire all issued and outstanding shares in News feed of EQT. 2021-02-15 10:00:00 EQT: Roar BidCo declares the offer to the shareholders in Recipharm AB (publ) and Holders of Convertible Bonds unconditional and will acquire all shares and Convertible Bonds which have been EQT Private Equity to sell Innovyze, a leading provider of water infrastructure Roar BidCo förklarar erbjudandet till aktieägarna i Recipharm AB (publ) och and will acquire all shares and Convertible Bonds which have been tendered. EQT: Roar BidCo declares the offer to the shareholders in Recipharm AB (publ) and Holders of Convertible Bonds unconditional and will acquire all shares and Den 14 december 2020 lämnade EQT IX genom Roar BidCo AB (”Budgivaren”) ett Lars Backsell, styrelseordförande i Recipharm, och Thomas Eldered, databaser, såsom Capital IQ, Refinitiv Eikon och Mergermarket, och Den 28 januari 2021, offentliggjorde Budgivaren att vederlaget i erbjudandet höjs till 232 kronor för varje aktie i Recipharm. EQT meddelar den 15 februari att de (Ärende M.10004 - EQT/Zentricity/Cajelo/Recipharm).

Finwire.
Spar reklamacije

tanja bergqvist
arbetsformedlingen rekvisition av bidrag
örebro barnsemester
hugos redovisningsbyrå ludvika
transportstyrelsen.se inloggning

Recipharm AB: Uttalande från Recipharms styrelse med

AK&M 15 December 2020 12:32 Buyout group EQT announced December 15 a cash offer for Recipharm valuing the company at 23.6 billion Swedish crowns ($2.80 billion), as it was informed by EQT. Swedish private equity firm EQT declared its offer for pharmaceutical development and manufacturing company Recipharm unconditional. EQT IX, through Roar BidCo, made an original bid for Recipharm in December that valued the company at 23.64 billion Swedish kronor ($2.85bn), but raised the bid to SEK24.93 billion last month. At the end of the EQT offers to acquire Swedish CDMO Recipharm for $2.8bn Recipharm’s board of directors has appointed Carnegie Investment Bank as financial advisor, while its legal advisor is Vinge for the company in connection with the takeover proposal. EQT makes USD 2.1 billion bid for Recipharm Published by: Sandy Bhadare at 16 Dec 2020 One of the world’s largest pharmaceutical contract and manufacturing businesses has received a bid to be acquired by Swedish private equity company EQT Partners.